MedTrace Logo

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06155422 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 670

Last updated 2023-12-04

No results posted yet for this study

Summary

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

DRUG

Cadonilimab

recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment

Sponsors & Collaborators

  • Gang Chen (101199)

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2026-11-30
Completion
2027-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155422 on ClinicalTrials.gov